ČEŠKOVÁ, Eva. Farmakorezistentní deprese - jak dál? (Pharmacoresistant depression – what is the next step?). Psychiatrie pro praxi. Olomouc: Solen s.r.o., 2016, vol. 17, No 3, p. 92-95. ISSN 1213-0508.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Farmakorezistentní deprese - jak dál?
Name (in English) Pharmacoresistant depression – what is the next step?
Authors ČEŠKOVÁ, Eva (203 Czech Republic, guarantor, belonging to the institution).
Edition Psychiatrie pro praxi, Olomouc, Solen s.r.o. 2016, 1213-0508.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14740/16:00091237
Organization unit Central European Institute of Technology
Keywords in English pharmacoresistant depression; combination of antidepressants; augmentation; multimodal/multifunctional antide - pressants
Tags rivok
Changed by Changed by: Mgr. Eva Špillingová, učo 110713. Changed: 23/3/2017 15:16.
Abstract
Farmakorezistentní deprese (treatment resistant depression, TRD) je spojena s vyšším rizikem suicidia a špatnou prognózou. Léčba je problematická. Než sáhneme k doporučeným postupům, tj. změně antidepresiva, augmentaci a kombinaci antide - presiv, měli bychom zhodnotit diagnostické aspekty, hlavně komorbiditu a adekvátnost dosavadní léčby včetně adherence. Často používané kombinace antidepresiv a augmentace antipsychotiky 2. generace nesou s sebou všechny nevýhody poly - terapie. Další možnost nabízí monoterapie multimodálními/multifunkčními antidepresivy, která postihují více molekulárních cílů různými mechanizmy. Studie v tomto směru zatím chybí.
Abstract (in English)
Pharmacoresistant depression (treatment resistant depression, TRD) is associated with a higher suicidal risk of suicides and poor prognosis. Its management is a challenge. Before using the recommended strategies for TRD i.e. switch to another antidepressant, augmentation and combination of antidepressant, we should evaluate the diagnosis, mainly comorbidity and adequacy of previous treatment including adherence. Frequently used strategies such as augmentation and combinations have all disadvantages of polytherapy. An interesting option for TRD is monotherapy with multimodal/multifunctional antidepressants, aiming at several molecular targets with different mechanism of action. Clinical studies in this indication have not been done.
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
PrintDisplayed: 22/7/2024 23:27